{"id":"NCT02373202","sponsor":"Sanofi","briefTitle":"A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)","officialTitle":"A Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02","primaryCompletion":"2016-11","completion":"2016-11","firstPosted":"2015-02-26","resultsPosted":"2018-01-30","lastUpdate":"2018-01-30"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Sarilumab","otherNames":["SAR153191 (REGN88)"]},{"type":"DRUG","name":"Sulfasalazine","otherNames":[]},{"type":"DRUG","name":"Leflunomide","otherNames":[]},{"type":"DRUG","name":"Bucillamine","otherNames":[]},{"type":"DRUG","name":"Tacrolimus","otherNames":[]},{"type":"DRUG","name":"Mizoribine","otherNames":[]}],"arms":[{"label":"Sarilumab 150 mg q2w + DMARDs","type":"EXPERIMENTAL"},{"label":"Sarilumab 200 mg q2w + DMARDs","type":"EXPERIMENTAL"},{"label":"Sarilumab 150 mg q2w","type":"EXPERIMENTAL"},{"label":"Sarilumab 200 mg q2w","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo document the long-term safety of sarilumab added to non-methotrexate (non-MTX) disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.\n\nSecondary Objective:\n\nTo document the long term efficacy of sarilumab added to non-MTX DMARDs or as monotherapy.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline up to Week 58","effectByArm":[{"arm":"Sarilumab 150 mg q2w + DMARDs","deltaMin":14,"sd":null},{"arm":"Sarilumab 200 mg q2w + DMARDs","deltaMin":13,"sd":null},{"arm":"Sarilumab 150 mg q2w","deltaMin":25,"sd":null},{"arm":"Sarilumab 200 mg q2w","deltaMin":28,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":40,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Nasopharyngitis","Stomatitis","Neutropenia","Injection site erythema","Rheumatoid arthritis"]}}